Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials

被引：0
|
作者：
Deodhar, Atul A. [1 ]
Baeten, Dominique [2 ]
Sieper, Joachim [3 ]
Porter, Brian [4 ]
Widmer, Albert [5 ]
Richards, Hanno [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA
[2] Univ Amsterdam, Acad Med Ctr, Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Clin Benjamin Franklin, Berlin, Germany
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
SIGNIFICANTLY IMPROVES SIGNS; PLACEBO-CONTROLLED TRIAL; MONOCLONAL-ANTIBODY; INTERLEUKIN-17A; SYMPTOMS; PHASE-3;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2887
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis
    Liu, Wei
    Wu, Yuan-hao
    Zhang, Lei
    Liu, Xiao-ya
    Xue, Bin
    Liu, Bin
    Wang, Yi
    Ji, Yang
    SCIENTIFIC REPORTS, 2016, 6
  • [22] Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial
    Bao, Chunde
    Huang, Feng
    Khan, Muhammad Asim
    Fei, Kaiyin
    Wu, Zhong
    Han, Chenglong
    Hsia, Elizabeth C.
    RHEUMATOLOGY, 2014, 53 (09) : 1654 - 1663
  • [23] Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
    Baraliakos, Xenofon
    Deodhar, Atul
    Dougados, Maxime
    Gensler, Lianne S.
    Molto, Anna
    Ramiro, Sofia
    Kivitz, Alan J.
    Poddubnyy, Denis
    Oortgiesen, Marga
    Vaux, Thomas
    Fleurinck, Carmen
    Shepherd-Smith, Julie
    de la Loge, Christine
    de Peyrecave, Natasha
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (12) : 1943 - 1958
  • [24] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
    Baeten, Dominique
    Blanco, Ricardo
    Geusens, Piet
    Sieper, Joachim
    Tseng Jui-Cheng
    Martin, Ruvie
    Porter, Brian
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [25] Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials
    Christian Lampl
    Viktoria Kraus
    Katrina Lehner
    Brett Loop
    Mahan Chehrenama
    Zofia Maczynska
    Shannon Ritter
    Jan Klatt
    Josefin Snellman
    The Journal of Headache and Pain, 2022, 23
  • [26] Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials
    Lampl, Christian
    Kraus, Viktoria
    Lehner, Katrina
    Loop, Brett
    Chehrenama, Mahan
    Maczynska, Zofia
    Ritter, Shannon
    Klatt, Jan
    Snellman, Josefin
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [27] Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
    Kereiakes, Dean J.
    Lepor, Norman E.
    Gerber, Robert
    Lee, L. Veronica
    Elassal, Joe
    Thompson, Desmond
    Gibson, C. Michael
    ATHEROSCLEROSIS, 2018, 277 : 211 - 218
  • [28] Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
    Helliwell, Philip S.
    Gladman, Dafna D.
    Chakravarty, Soumya D.
    Kafka, Shelly
    Karyekar, Chetan S.
    You, Yin
    Campbell, Kim
    Sweet, Kristen
    Kavanaugh, Arthur
    Gensler, Lianne S.
    RMD OPEN, 2020, 6 (01):
  • [29] Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study
    Tlustochowicz, Witold
    Rahman, Proton
    Seriolo, Bruno
    Krammer, Gerhard
    Porter, Brian
    Widmer, Albert
    Richards, Hanno B.
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (03) : 495 - 503
  • [30] Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials
    Wu, D.
    Hou, S. -Y.
    Zhao, S.
    Hou, L. -X.
    Jiao, T.
    Xu, N. -N.
    Zhang, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (06) : 992 - 1003
12345